Orantinib is a multiple receptor tyrosine kinase inhibitor with IC50s of 2.1 μM, 8 nM and 1.2 μM for VEGF-R1, PDGF-Rβ and FGF-R1, respectively. It has greatest potency against PDGFR autophosphorylation.
Products > Drug Discovery > Inhibitor | Products > Drug Discovery > Inhibitor | Neurological Disease | FGFR
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.